• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 8:01:50 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UNCY alert in real time by email
    false 0001766140 0001766140 2025-05-14 2025-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 14, 2025

     

    Unicycive Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware    001-40582   81-3638692
    (State or other jurisdiction of    (Commission File Number)   IRS Employer
    incorporation or organization)       Identification No.)

     

    4300 El Camino Real, Suite 210

    Los Alto, CA 94022

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (650) 351-4495

     

    (Former name or former address, if changed since last report)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:    Trading Symbol(s)    Name of each exchange on which registered: 
    Common Stock    UNCY   Nasdaq Capital Market 

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:

     

    ☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

     

    Emerging growth company   ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Conditions.

     

    On May 14, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

     

    The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits.

     

    99.1   Press Release of Unicycive Therapeutics, Inc. dated May 14, 2025.
    104   Cover Page Interactive Data File (embedded within Inline XBRL document).

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 14, 2025

     

      UNICYCIVE THERAPEUTICS, INC.
       
      By: /s/ Shalabh Gupta
        Shalabh Gupta
        Chief Executive Officer

     

     

    2

     
    Get the next $UNCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UNCY

    DatePrice TargetRatingAnalyst
    4/21/2025$6.00Buy
    Guggenheim
    4/4/2024$9.00Overweight
    Piper Sandler
    8/9/2021$13.50Buy
    Roth Capital
    More analyst ratings

    $UNCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To request a 1x1 meeting with management, please contact your Needham representative. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments f

      4/1/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

            - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for

      3/31/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

      LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh

      9/6/23 7:03:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

      LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal

      10/26/21 7:30:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

      Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

      4/21/25 8:39:22 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Unicycive Therapeutics with a new price target

      Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00

      4/4/24 8:18:34 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Unicycive Therapeutics with a new price target

      Roth Capital initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $13.50

      8/9/21 9:57:19 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:56:41 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

      SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      5/15/25 4:39:09 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

      5/14/25 8:01:50 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Financials

    Live finance-specific insights

    See more
    • Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

      5/14/25 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

            - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for

      3/31/25 7:00:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

      – OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update. "We are pleased with the

      11/13/24 7:15:00 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aggarwal Gaurav converted options into 1,400,000 shares (SEC Form 4)

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      2/19/25 11:55:27 AM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Aggarwal Gaurav converted options into 5,500,000 shares (SEC Form 4)

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      10/10/24 5:15:20 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Townsend John

      4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

      8/14/24 4:15:20 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UNCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:13:38 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 7:01:14 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

      SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

      11/14/24 5:46:12 PM ET
      $UNCY
      Biotechnology: Pharmaceutical Preparations
      Health Care